1,25-Dihydroxyvitamin D3 Induces N-Myc Downstream Regulated Gene-2 Expression In Papillary Thyroid Carcinoma Cells

Year 2020, Volume: 4 Issue: 2, 128 - 132, 01.06.2020

Murat Sipahi Didem Keleş Bartık Mehmet Doruk Fırat Bayraktar Gülgün Oktay

https://doi.org/10.30621/jbachs.2020.1012

Abstract

Purpose: In addition to its role in serum calcium homeostasis, the anti-tumor function of 1,25-dihydroxyvitamin D3 calcitriol in cancer development is well established. N-myc Downstream Regulated Gene 2 which functions as a tumor suppressor gene has recently been shown to be downregulated in various cancer leading to increased tumor incidence, progression and metastasis. The goal of this study was to investigate the possible effects of calcitriol treatment on NDRG2 expression in BCPAP papillary thyroid carcinoma cells.Methods: The experiments were carried on human primary thyroid follicular epithelial cells , and human papillary thyroid carcinoma cells BCPAP . The half maximal inhibitory concentration IC50 of calcitriol on BCPAP cells was determined by WST-1 assay. BCPAP cells were treated with 15 and 30µM calcitriol for 24, 48, and 72 hours, respectively. Basal NDGR2 expression in Nthy-ori-3–1 and BCPAP cells as well as the alterations on NDRG2 expression in calcitriol treated BCPAP cells were evaluated with western blot.Results: A significant downregulation of NDRG2 was observed in BCPAP cells when compared to Nthy-ori-3–1 cells p

Keywords

1, 25-Dihydroxyvitamin D3, thyroid cancer, papillary thyroid cancer, N-myc downstream regulated gene 2

References

• Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer 2011;2:193–199. [CrossRef]
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985–1995. Cancer 1998;83:2638–2648. [CrossRef]
• Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53–58. [CrossRef]
• Moore DD, Kato S, Xie W, et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006;58:742–759. [CrossRef]
• Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325–349. [CrossRef]
• Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862– 46868. [CrossRef]
• Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1, 25-dihydroxyvitamin D3 through the down- regulation of telomerase. J Biol Chem 2004;279:53213–53221. [CrossRef]
• Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009;69:967–975. [CrossRef]
• Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076–1082. [CrossRef]
• Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369–387. [CrossRef]
• Qu X, Zhai Y, Wei H, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem 2002;229:35–44. [CrossRef]
• Zhang J, Li F, Liu X, et al. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem 2006;281:39159–39168. [CrossRef]
• Piepoli A, Cotugno R, Merla G, et al. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics 2009;2:11. [CrossRef]
• Liu N, Wang L, Liu X, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun 2007;358:164–169. [CrossRef]
• Lee DC, Kang YK, Kim WH, et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 2008;68:4210–4220. [CrossRef]
• Choi SC, Yoon SR, Park YP, et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med 2007;39:705–714. [CrossRef]
• Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-586S. [CrossRef]
• Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 2006;54:355–361. [CrossRef]
• Clinckspoor I, Hauben E, Verlinden L, et al. Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem 2012;60:502–511. [CrossRef]
• Stepien T, Krupinski R, Sopinski J, et al. Decreased 1–25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 2010;41:190–194. [CrossRef]
• Okano K, Usa T, Ohtsuru A, et al. Effect of 22-oxa-1, 25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J 1999;46:243–252. [CrossRef]
• Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 2002;160:511–519. [CrossRef]
• Zou M, Baitei EY, BinEssa HA, et al. Cyp24a1 Attenuation Limits Progression of Braf (V600E)-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF (V600E) Inhibitor PLX4720. Cancer Res 2017;77:2161–2172. [CrossRef]
• He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509–1512. [CrossRef]
• Larriba MJ, Valle N, Palmer HG, et al. The inhibition of Wnt/beta- catenin signalling by 1alpha, 25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr Relat Cancer 2007;14:141–151. [CrossRef]
• Zhao H, Zhang J, Lu J, et al. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 2008;8:303. [CrossRef]
• Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M. Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol 1998;185:267–272. [CrossRef]
• Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down- regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001;158:987–996. [CrossRef]